Evaluation of Aminocamptothecin (9-AC, NSC #603071 [IDEC 132]) in Recurrent, Platinum Resistant and Refractory Ovarian Cancer and Primary Peritoneal Carcinoma

Trial Profile

Evaluation of Aminocamptothecin (9-AC, NSC #603071 [IDEC 132]) in Recurrent, Platinum Resistant and Refractory Ovarian Cancer and Primary Peritoneal Carcinoma

Completed
Phase of Trial: Phase II

Latest Information Update: 20 Jun 2013

At a glance

  • Drugs IDEC 132 (Primary)
  • Indications Ovarian cancer; Peritoneal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Nov 2007 Status changed from in progress to completed.
    • 17 Sep 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top